Replies to post #3320 on Theralase Technologies Inc (TLTFF)

[123414]

Can look at rev projections for NMIBC refractory treatment in Loe's assessment. The brain and lung work currently are not priced in.

Bladder cancer-targeted PDT TLD-1433 is a major value driver in our model
http://67.212.93.22/research/content/20170905TLT%20final.pdf


So at this price we are at like 2013 year study levels. This one will break its range.